Advancing Claudin-1 Expression Research with Cutting-edge Technologies
KYAN Technologies,Alentis Therapeutics,and CELLphenomics Join Forces Combining Cutting-edge Optim.AI™ and PD3D® Models to Advance Claudin-1 Expression Research SINGAPORE, SINGAPORE, September 30, 2023 /EINPresswire.com/ — KYAN Technologies, a vanguard combinatory drug development solutions provider, is thrilled to announce a strategic partnership with Alentis Therapeutics, a clinical-stage biopharmaceutical company developing breakthrough treatments for Claudin-1 positive tumours and…
Read More “Advancing Claudin-1 Expression Research with Cutting-edge Technologies” »
